Clinical Success Lifts Vera (VERA) Shares, Boosting Fund Returns

Group 1: Voya MidCap Opportunities Fund Overview - The Voya MidCap Opportunities Fund's Q4 2025 investor letter highlights solid market gains but notes relative underperformance against the Russell Mid Cap Growth Index due to unfavorable stock selection [1] - The fund managers maintain a cautiously constructive outlook, emphasizing the importance of active and flexible positioning amid ongoing geopolitical risks and policy uncertainty [1] - The letter indicates that broadening market leadership, sustained corporate capital expenditure, and AI-led innovation could support future returns [1] Group 2: Vera Therapeutics, Inc. Performance - Vera Therapeutics, Inc. was a top contributor to the fund's performance in Q4 2025, driven by positive phase three clinical trial results for its kidney disease treatment [3] - At the end of Q4 2025, Vera Therapeutics represented 0.93% of the fund's portfolio, with a one-month return of -9.09% and a trading range of $18.53 to $56.05 over the past 52 weeks [2] - As of January 22, 2026, Vera Therapeutics' stock closed at approximately $45.77 per share, with a market capitalization of about $3.249 billion [2] Group 3: Hedge Fund Interest and Market Position - Vera Therapeutics was held by 36 hedge fund portfolios at the end of Q3 2025, a decrease from 40 in the previous quarter [4] - The investment community acknowledges the risks and potential of Vera Therapeutics but expresses a stronger conviction in AI stocks for higher returns in a shorter timeframe [4]